AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
NEW YORK, Feb. 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Columbia on behalf of investors who purchased Mallinckrodt plc (NYSE:MNK) securities between November 25, 2014, and January 18, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/mallinckrodt-plc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Mallinckrodt and its acting President and Chief Executive Officer, Mark Trudeau, misrepresented the efficacy of Mallinckrodt’s business model and its ability to maintain sustainable revenue. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that Mallinckrodt engaged in unlawful anticompetitive practices to maintain H.P. Acthar Gel’s (“Acthar”) monopoly status as the only FDA-approved therapeutic preparation of adrenocorticotropic hormone and that Mallinckrodt’s increasing reliance on Medicare and Medicaid meant that the Company’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for the drug by taxpayers.
If you suffered a loss in Mallinckrodt you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/mallinckrodt-plc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
